Christopher Moxham
Amministratore Delegato presso Rarebase, PBC
Profilo
Christopher Moxham is currently the President & Chief Executive Officer at Rarebase, PBC.
Previously, he worked as the Head-Drug Discovery at Eli Lilly & Co. and as the Senior Vice President-Discovery at Fulcrum Therapeutics, Inc. He holds a doctorate degree from Stony Brook University and an undergraduate degree from Cornell University.
Posizioni attive di Christopher Moxham
| Società | Posizione | Inizio |
|---|---|---|
Rarebase, PBC
 Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Amministratore Delegato | 04/10/2023 |
Precedenti posizioni note di Christopher Moxham
| Società | Posizione | Fine |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| FULCRUM THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Christopher Moxham
| Cornell University | Undergraduate Degree |
| Stony Brook University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Aziende private | 1 |
|---|---|
Rarebase, PBC
Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Technology Services |
- Borsa valori
- Insiders
- Christopher Moxham
